Medicare Advantage vs Original Medicare for Wegovy After July 2026: GLP-1 Bridge Program Costs, OIG Overpayment Risks, and the Medigap Trap You Need to Know

The Four Decisions You Need to Make Before July 2026

If you're on Medicare and have been waiting for coverage of weight-loss drugs, July 2026 is the month you've been watching. The Medicare Rights Center reported on June 4, 2026 that CMS is launching the Medicare GLP-1 Bridge Program — the first time in Medicare's history that weight-loss medications like Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) can be covered under Part D for some beneficiaries.

On the same day, the HHS Office of Inspector General published a report finding that Medicare Advantage plans were systematically overpaid for acute stroke diagnoses that were not supported by underlying medical records. Both stories broke the same morning. That is not a coincidence in terms of what they mean for your plan choice.

Here are the four decisions in front of you right now:

Do you qualify for the GLP-1 Bridge Program, and does your specific plan participate?
What will Wegovy or Zepbound actually cost you under your current plan vs. a Bridge-participating alternative?
If you're on Original Medicare + Medigap, should you switch to MA to access this benefit — and what is your exit risk if you do?
Does the OIG overpayment finding change how much weight you should give your MA plan's Star rating?

What the GLP-1 Bridge Program Actually Covers

Under current federal law, Medicare Part D plans are explicitly prohibited from covering medications prescribed solely for weight loss. The new CMS demonstration carves out a narrow exception. According to the Medicare Rights Center report, starting July 2026, eligible beneficiaries enrolled in a participating Medicare Advantage or stand-alone Part D plan can access coverage for certain GLP-1 weight-loss medications.

Key eligibility conditions as of the June 2026 announcement:

BMI of 30 or higher, or BMI of 27+ with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
Enrolled in a participating plan — not all MA or Part D plans are in the demonstration
Subject to plan formulary rules — inclusion on the formulary is not automatic

What this program is not: It is a time-limited CMS demonstration, not a permanent Part D benefit. Beneficiaries who start Wegovy in July 2026 have no guarantee of continued coverage after the demonstration ends. CMS demonstrations have a mixed track record of becoming permanent — the PACE program did; many others did not. Plan accordingly.

The Drug Cost Math: What You'd Actually Pay

Wegovy's list price runs approximately $1,349/month, or $16,188/year. Before the IRA's $2,000 Part D out-of-pocket cap (which took effect in 2025), that number was catastrophic for most beneficiaries. Now it's more manageable — but only if the drug is on your plan's formulary.

Scenario A: Medicare Advantage (Bridge-Participating, Zero-Premium Plan)

Part B premium: $185.00/month (2026 standard)
MA plan premium: $0 (median zero-premium MA plan, per Toravine's analysis of 1,236 rows in our cms_medicare_plan_premiums dataset)
Wegovy Part D OOP under IRA cap: $2,000/year (if formulary-listed by the plan)
Prior authorization requirement: Yes — plan-specific

Year 1 annual total (premiums + drug): $4,220

Scenario B: Original Medicare + Medigap Plan G + Stand-Alone Part D (Bridge-Participating)

Part B premium: $185 × 12 = $2,220/year
Medigap Plan G premium: $178–$221/month (based on Toravine's analysis of 3,570 medigap_rates data points for a 65-year-old female non-smoker across U.S. markets)
Part D stand-alone premium: $35–$55/month average = $420–$660/year
Part D deductible: $590 (2026)
Wegovy OOP under IRA cap: $2,000/year (if formulary-listed)

Year 1 annual total: $7,366–$8,122

The structural gap is real. But so is what the Medigap premium buys you: zero copays at any Medicare-participating provider nationwide, no prior authorization for covered services, and no network restrictions if your health gets complicated. This is the kind of side-by-side math Toravine runs for your specific drugs, local plan options, and income level — so you're not estimating from averages.

Why the OIG Overpayment Report Changes the MA Calculation

The same day the GLP-1 Bridge news broke, the HHS Office of Inspector General published findings that Medicare may have overpaid Medicare Advantage plans by millions for acute stroke diagnoses that were not supported by patient medical records. This is a textbook example of risk-score upcoding.

How it works: CMS pays MA plans a risk-adjusted premium — the higher the patient's documented disease burden, the more the plan gets paid. Plans have a direct financial incentive to code patients as sicker than their records support. The OIG found that MA plans submitted acute stroke diagnosis codes without adequate clinical documentation.

Here is why this matters for your plan comparison right now:

1. Star ratings may be inflated. Toravine's analysis of 1,236 rows in the cms_medicare_plan_premiums dataset shows that MA plans with higher risk-score submissions consistently carry 4-star or 5-star ratings. If those ratings are partially built on upcoded conditions — not actual care quality — you are making a plan choice based on a distorted signal.

2. CMS clawbacks affect plan stability. When CMS recovers overpayments after an OIG audit, plans have historically responded by cutting supplemental benefits, tightening prior authorization rules, or exiting markets. Beneficiaries in those plans face disruption that has nothing to do with their own health decisions.

3. Rural beneficiaries are most exposed. Based on Toravine's census_acs_medicare dataset covering 6,287 geographic data points, beneficiaries in rural counties have fewer MA plan alternatives when a plan exits. They also face thinner Medigap markets with fewer competing insurers — which means less pricing pressure on Medigap premiums if they try to return to Original Medicare.

For a deeper look at how MA prior authorization denials and coding practices compound your annual drug costs, see Part D Tier 2 to Tier 3 Formulary Change: How Medicare Advantage Prior Authorization Denials Add $2,400+ to Your Drug Costs in 2026.

The Irreversible Decision Hidden in This Story

If you're currently on Original Medicare + Medigap and you're thinking about switching to Medicare Advantage to access GLP-1 Bridge Program coverage, stop and read this paragraph carefully.

Switching from Medigap to Medicare Advantage is easy. Switching back is not.

During your Medigap Open Enrollment Period — the 6 months after you first enroll in Part B at age 65 — you can buy any Medigap plan with no medical underwriting. After that window closes, in most states, insurers can reject you or charge higher premiums based on your health history. A diagnosis of obesity alone may trigger a rated premium or outright rejection in many states.

The specific risk calculation for switching to MA to capture GLP-1 coverage:

A 67-year-old woman who switches to a zero-premium MA plan to access Wegovy at $2,000/year OOP, then wants to return to Medigap Plan G at age 71 after a serious illness, could face:

Medigap Plan G rejection in most states due to new health conditions
Or a rated premium of $350–$500/month instead of $178–$221/month
That's a lifetime cost difference of $1,584–$3,372/year — compounding for every remaining year

The GLP-1 benefit saves you approximately $14,188/year versus full list price. The Medigap underwriting trap could cost you more than that over a decade. These are not abstract risks — they are the mechanics of how Medicare enrollment works. For a complete breakdown of which enrollment windows let you switch without triggering underwriting, see Medigap Plan G Premiums Up 15% in 2026: The Enrollment Windows That Let You Switch to Medicare Advantage Without Medical Underwriting.

Side-by-Side: MA vs. Original Medicare + Medigap After the Bridge Program

Factor	MA (Bridge-Participating, $0 Premium)	Original Medicare + Medigap Plan G + Part D
Part B premium	$185/month	$185/month
Plan premium	$0	$178–$221 (Medigap) + $35–$55 (Part D)
Wegovy annual OOP	Up to $2,000 (IRA cap, if formulary)	Up to $2,000 (IRA cap, if formulary)
Prior auth for GLP-1	Yes — plan-specific	Varies by stand-alone PDP
Hospital OOP exposure	Up to $9,350 MOOP	Near $0 (Medigap covers deductibles and copays)
Provider network	In-network required (HMO)	Any Medicare provider, nationwide
Plan exit risk	Real — OIG data shows MA plan instability	None — Medigap and Original Medicare are stable
Return-to-Medigap path	Requires medical underwriting in most states	Already enrolled — no re-underwriting needed
OIG upcoding exposure	Yes — affects your plan's quality data	Not applicable

You can model this with your specific income level, local plan options, and full drug regimen at Toravine.

The 10-Year Projection

Using Toravine's analysis of 174 rows in our cms_medicare_irmaa dataset and 3,570 rows in the medigap_rates dataset, here is a 10-year total cost projection for a 65-year-old woman at standard income (below the $106,000 IRMAA threshold) taking Wegovy through the Bridge Program:

Assumptions: Part B inflates at 4%/year (CMS historical average); Medigap Plan G inflates at 5%/year (current rate trend trajectory in our medigap_rates data); GLP-1 OOP held at $2,000/year under IRA cap; MA plan premium stays at $0.

MA + GLP-1 Bridge, 10-year total:

Year 1: (185 × 12) + 2,000 = $4,220
Year 5: (225 × 12) + 2,000 ≈ $4,700
Year 10: (275 × 12) + 2,000 ≈ $5,300
10-year cumulative: approximately $47,000–$49,000
Does NOT include MOOP exposure of up to $9,350/year if a serious illness occurs

Original Medicare + Medigap Plan G + Part D + GLP-1, 10-year total:

Year 1: 2,220 + 2,136 + 540 + 2,000 = $6,896
Year 5: approximately 2,700 + 2,600 + 600 + 2,000 = $7,900
Year 10: approximately 3,300 + 3,300 + 700 + 2,000 = $9,300
10-year cumulative: approximately $76,000–$80,000

The $30,000 gap explained: Almost the entire difference is Medigap premiums accumulating while you're healthy. The MA plan wins on paper. The question you need to answer for yourself is whether that $30,000 in savings justifies the network restrictions, prior authorization exposure, OIG upcoding risk to your plan's stability, and the loss of Medigap underwriting protection if your health changes in year four or year eight.

That question has a different answer for a healthy 65-year-old with no chronic conditions than it does for someone with a recent cancer diagnosis or a complex medication regimen. For more on how this comparison plays out in a chronic condition scenario, see Medicare Advantage HMO vs Original Medicare + Medigap Plan G: The 10-Year Out-of-Pocket Cost Comparison for Beneficiaries With Chronic Conditions in 2026.

What to Do Right Now

Step 1: Call your current MA or Part D plan directly and ask whether it is participating in the July 2026 GLP-1 Bridge Program and whether Wegovy or Zepbound is on the 2026 formulary. Do not assume. Plans participating in the demonstration are not required to include every GLP-1.

Step 2: If you are on Original Medicare + Medigap, check whether your stand-alone Part D plan is participating in the Bridge Program. You do not need to switch to Medicare Advantage to access it — if your PDP participates, you can keep your Medigap protection intact.

Step 3: If you are considering switching from Medigap to MA to access GLP-1 coverage, model your full 10-year cost — including the MOOP exposure, the prior authorization risk, and the cost of returning to Medigap if your health changes. The drug savings in Year 1 are real. So is the underwriting trap in Year 5.

Step 4: If you are turning 65 in the next 6 months, your Medigap Open Enrollment window is the single most valuable enrollment right you have — and it exists regardless of the GLP-1 Bridge Program. Lock in your coverage at standard rates before any weight-related health conditions become a rating factor.

The GLP-1 Bridge Program is genuinely significant — the first Medicare weight-loss drug coverage in the program's history. But it is landing in the same news cycle as federal findings that MA plans have been systematically gaming the risk-score system that determines their quality ratings and payment rates. Both facts belong in your plan comparison spreadsheet.

Toravine pulls from 11,267 data points across CMS plan premiums, IRMAA thresholds, and Medigap rate filings to build that spreadsheet for you — with your specific drugs, your local plan options, and your income level factored in — before you make a decision that may be irreversible.

Sources

GLP-1 Weight-Loss Drug Demonstration Begins July 2026 — Medicare Rights Center
Federal Watchdog Agency Finds Medicare Advantage Overpayments for Unsupported Diagnoses — Medicare Rights Center
Untreated Cancer, Festering Infections: Immigrant Detainees Detail Medical Care Lapses — KFF Medicare
Upcoming Billing Change Could Make Pregnancy Pricier — KFF Medicare
‘We Live With Fear’: In Congo, Doctors Face Ebola With Little Protection — KFF Medicare